PV Bulletin

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

The Therapeutics Goods Administration (TGA) published key discussions from the sixth Human Research Ethics Committee (HREC) and TGA Clinical Trials Discussion Forum.

Primary source: https://www.tga.gov.au/resources/publication/meeting-statements/human-research-ethics-committee-and-tga-clinical-trials-discussion-forum-communique-meeting-6-14-july-2026

PV Impact Brief

Urgency: HighConfidence: high

What changed

Clinical trial sponsors and investigators must review and comply with the updated ISO 14155 standards for medical device clinical safety reporting, especially in light of the discussions regarding N=1 therapeutics and their ethics oversight.

Why it matters

The discussions emphasize the importance of robust ethics oversight and safety monitoring for personalized therapeutics, ensuring that clinical trials adhere to the latest standards.

Action needed

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Relevant for
Regulatory Intelligence LeadPV Quality Lead
Processes impacted
Inspection ReadinessICSR
Owner

Regulatory Intelligence Lead

Review cadence

Review before 2026-07-20.

Policy change details

Document type
Notice
Policy status
final
Publication date
2026-07-20
Effective date
2026-07-20
Policy change
TGA published the communique from the sixth HREC/TGA Clinical Trials Discussion Forum held on July 14, 2026. The forum discussed ethics and regulatory oversight for N=1 therapeutics and provided updates on medical device regulations, including ISO 14155 changes and high-risk Clinical Trial Notification (CTN) reviews for the 2025/26 period.

Key changes

Clarification on ethics oversight and regulation for N=1 therapeutics; updates on ISO 14155 (Clinical investigation of medical devices) implementation; outcomes of 2025/26 high-risk CTN reviews.

Affected workflows

Inspection ReadinessICSR

Responsible groups

Clinical SafetyRegulatory AffairsQuality Assurance

PV impact

Clinical trial sponsors and investigators should review the updates on ISO 14155 to ensure compliance with medical device clinical safety reporting standards. The discussions on N=1 research emphasize the need for robust ethics oversight and safety monitoring for personalized therapeutics.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jul 20, 2026

Full briefing

Practical implication

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

The TGA's sixth HREC/TGA Clinical Trials Discussion Forum addressed important updates related to ISO 14155 and the regulatory requirements for N=1 therapeutics. These updates stress the need for clinical trial sponsors to ensure compliance with medical device clinical safety reporting standards, particularly focusing on high-risk Clinical Trial Notification reviews for the 2025/26 period.

What changed: Clinical trial sponsors and investigators must review and comply with the updated ISO 14155 standards for medical device clinical safety reporting, especially in light of the discussions regarding N=1 therapeutics and their ethics oversight.

Why it matters: The discussions emphasize the importance of robust ethics oversight and safety monitoring for personalized therapeutics, ensuring that clinical trials adhere to the latest standards.

Practical implication: Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Therapeutic Goods Administration (TGA)#final#Reporting Requirement#policy-change#firecrawl-policy-agent#Notice

Related updates for your role

publicFDA · USA · Updated Sep 1, 2026

FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels

Urgency: High

Healthcare providers must utilize updated labels and ensure phosphate levels are monitored in at-risk patients and those receiving repeat therapy within three months.

LabelingLabeling Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Labeling Lead, Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 1, 2026

Regulatory acceptance of new approach methodologies (NAMs) to reduce animal use testing

Urgency: High

Developers of NAMs are encouraged to participate in early dialogues with EMA and are now able to submit NAM-derived data for independent evaluation under a voluntary data submission pilot.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 1, 2026

MHRA Suspends Use of Avacopan Vifor to New Patients

Urgency: High

Healthcare professionals should not initiate treatment with Avacopan Vifor for new patients and must review existing patients' treatment plans to ensure safe transitions to alternative therapies.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 1, 2026

MHRA Regulatory Reform Amendments Tabled in Government’s Health Bill

Monitoring

Organizations involved in medical device compliance should prepare for potential future changes requiring MHRA-issued licenses for devices entering the market.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward